Clinical trial · Interventional
Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell Lymphoma
Evaluating Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography /Computed Tomography With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell Lymphoma
NCT02931201CI-TRIAL-00024237unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate whether a semi-quantitative interpretation using the liver SUVmax as reference can better interpret 18F-FDG PET/CT and predict disease progression during chemotherapy or survival in DLBCL.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma, Large B-Cell, Diffuse | Lymphoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-FDG PET/CT | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- DLBCL patients with 18F-FDG PET/CT
- description
- 18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria
- interventionNames
- Device: 18F-FDG PET/CT
Primary outcomes (1)
- measure
- Change from baseline in summed standardized uptake value (SUVmax) of lesion after 2 or 4 cycles
- timeFrame
- baseline(diagnosed by pathology and before chemotherapy) and 2 or 4 cycles after starting chemotherapy (each cycle 21days)
Secondary outcomes (1)
- measure
- 2 year progression-free survival
- timeFrame
- up to 2 years after initial diagnosis
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * newly diagnosed DLBCL * treated using an anthracycline-containing regimen with or without rituximab * minimal follow-up at 6 months after the completion of first-line treatment * complete medical history and clinicopathological data Exclusion Criteria: * secondary malignant disease * serious infection or inflammation (e.g., HIV) * primary central nervous system lymphoma * hepatic or renal dysfunction.
References
Publications (0)
Data not yet available
No reference posted for this study.